Clearmind Medicine Inc.
Clearmind Medicine Inc. is a U.S.-listed clinical-stage biotechnology company focused on discovering and developing non-hallucinogenic neuroplastogen-derived therapeutics. Its work centers on patented psychedelic-inspired compounds, including MEAI and CMND-100, for alcohol use disorder, binge-related behaviors, addiction, weight management, PTSD, and other central nervous system disorders, with operations and intellectual property activity spanning North America, Europe, and Asia.
Liiketoiminta
Osuus liikevaihdostaDrug candidates based on non-hallucinogenic psychedelic-inspired compounds such as MEAI and CMND-100.
Programs aimed at alcohol use disorder, binge drinking, binge eating, and gambling-related behaviors.
Research programs targeting PTSD and other psychiatric or stress-related disorders.
Compounds and formulations being developed for appetite, overeating, and related weight-control uses.
Patent filings, patent grants, and exclusive rights obtained through licensing agreements.
Asiakkaat
Clearmind primarily serves pharmaceutical and biotech stakeholders rather than mass-market end users: the near-term customer base is best understood as regulators, development partners, licensors, and future healthcare providers that would adopt its medicines if approved. In the commercialization phase, its products would ultimately be prescribed or recommended for patients with alcohol use disorder, binge-related behaviors, PTSD, and other CNS conditions. The company also relies on research and intellectual-property partners, including universities and licensing counterparties, to build and advance its pipeline.
Future end users of therapies for alcohol use disorder, binge drinking, binge eating, and gambling-related behaviors.
Prescribers who would use approved products to treat mental health and substance-use disorders.
Academic and IP counterparts that supply inventions, compounds, or collaborative development rights.
Potential partners that could help fund late-stage development or market approved candidates.
Strategia
Clearmind’s strategy is to build a broad, defensible intellectual-property estate around non-hallucinogenic psychedelic-derived compounds and use it to support future drug development and commercialization. The company is also extending patent coverage into multiple jurisdictions so that any eventual product can be protected across large addressable markets. Its licensing model with Yissum gives it exclusive global rights to develop and commercialize compounds while it advances the program through regulatory pathways.
Protects the company’s compounds and strengthens future partnering leverage.
Pipeline progress is required before any meaningful commercial opportunity can emerge.
Multiple regulatory and product pathways can improve the odds of eventual market entry.
Maantiede
Clearmind is incorporated and listed in the United States, with principal executive offices in Vancouver, Canada, and investor-facing activity across North America. Its patent strategy is international, with disclosed protection in the United States, Europe, and Hong Kong, reflecting an attempt to secure future commercialization rights in multiple major markets. The company’s business is therefore geographically defined more by where its intellectual property is protected and where future regulatory approvals may be sought than by current commercial sales.
Riskit
Clearmind faces the typical risks of clinical-stage biotechnology, where product candidates may fail in development, regulatory approval may be delayed, and patent protection may not translate into commercial products. Its reliance on a small number of compounds and on external licensing and valuation judgments also creates concentration risk and ongoing financing sensitivity. Because it has no disclosed commercial product sales in the provided materials, execution risk is centered on proving clinical utility, protecting IP, and funding development long enough to reach commercialization.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
The company’s value depends on proving that neuroplastogen candidates are safe and effective.
Kohdistuu - Regulatory approval uncertaintyVaikutus: KorkeaTodennäköisyys: Korkea
Drug candidates must satisfy multiple regulatory hurdles before commercialization.
Kohdistuu: Psychiatric and addiction indications
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Clinical-stage biotechnology typically requires repeated external capital raises.
Kohdistuu - Intellectual property dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The strategy relies on patents and exclusive licensing to secure market exclusivity.
Kohdistuu: Yissum license and global patent portfolio
Kirjanpito
Harkinnanvaraiset erätWarrants are marked to fair value each period, creating non-cash volatility.
Vaikutus: Can materially affect reported profit or loss
Expected volatility, life, risk-free rate, and adjustment probabilities drive estimates.
Vaikutus: Changes can significantly shift warrant valuations
Development-stage biotech companies must assess whether funding is sufficient to continue operations.
Vaikutus: Important for liquidity and solvency analysis
Debt and related-party funding affect liabilities, maturity profile, and financing risk.
Vaikutus: Influences leverage and near-term obligations
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Bright Minds Biosciences Inc
DRUG · Pharmaceutical Preparations
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
Psyence Biomedical Ltd
PBMWW · Pharmaceutical Preparations
Relmada Therapeutics, Inc
RLMD · Pharmaceutical Preparations
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
Definium Therapeutics, Inc.
DFTX · Medicinal Chemicals & Botanical Products
Päivitetty: 28.9.2026